Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Can Fite Biopharma Ltd ADR (CANF)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Can Fite Biopharma ADR's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Can Fite Biopharma ADR historical data, for real-time data please try another search
2.077 -0.023    -1.10%
16/02 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
ISIN:  US13471N3008 
CUSIP:  13471N300
  • Volume: 2,182
  • Bid/Ask: 1.780 / 1.800
  • Day's Range: 2.050 - 2.100
Can Fite Biopharma ADR 2.077 -0.023 -1.10%

Can Fite Biopharma Ltd ADR Company Profile

 
Get an in-depth profile of Can Fite Biopharma Ltd ADR, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

8

Equity Type

ADR

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

Contact Information

Address 26 Ben Gurion Street
Ramat Gan, 5257346
Israel
Phone 972 3 924 1114
Fax 972 3 924 9378

Top Executives

Name Age Since Title
Pnina Fishman 76 1994 Founder, Chief Scientific Officer & Executive Chairperson
Abraham Sartani 77 2001 Independent Director
Nabil Hanna 80 - Member of Scientific Advisory Board
Ilan Cohn 70 1994 Co-Founder & Director
Yaacov Goldman 69 2017 External Independent Director
Guy Regev 55 2011 Independent External Director
Scott L. Friedman - - Member of Clinical Advisory Board
Rifaat Safadi - - Member of Clinical Advisory Board
Arun J. Sanyal - - Member of Clinical Advisory Board
Stephen A. Harrison - 2023 Member of Clinical Advisory Board & Consulting Chief Medical Officer
Kim Papp - - Member of Clinical Advisory Board
Yoseph Bornstein 65 2021 Independent External Director
Salomon Stemmer - - Member of Clinical Advisory Board
Ohad Etzion - - Member of the Clinical Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CANF Comments

Write your thoughts about Can Fite Biopharma Ltd ADR
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ng Soon
Ng Soon Oct 08, 2021 11:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The most useless Israel
Ng Soon
Ng Soon May 27, 2021 1:29PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
☹️Israel company really waste of time..only falling and no upsize!!! Same with Teva ...
Ng Soon
Ng Soon May 06, 2021 12:32PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy?
Ng Soon
Ng Soon Mar 23, 2021 9:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Shift stock
Ng Soon
Ng Soon Mar 17, 2021 12:31PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Fall and fall ********
Omar Alhamad
Omar Alhamad Feb 22, 2021 8:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy buy buy
slava va
slava va Feb 11, 2021 9:34AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
2.8 EOD
ridzuan jalil
ridzuan jalil Feb 03, 2021 12:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
today 2.21
ridzuan jalil
ridzuan jalil Feb 03, 2021 12:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$5 are u sure?
Guy Rodman
Guy Rodman Feb 03, 2021 1:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it's only the beginning...this company will be more than 5$ this month
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email